Detalles de la búsqueda
1.
Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA.
J Comp Eff Res
; 12(1): e220127, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36440609
2.
Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States.
Clinicoecon Outcomes Res
; 15: 361-373, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37234086
3.
Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Mult Scler Relat Disord
; 70: 104472, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36566698
Resultados
1 -
3
de 3
1
Próxima >
>>